Ahead of the fourth quarter showcase from Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) anticipated March 7th, first …
H.C. Wainwright’s Ram Selvaraju commends new CEO Troy Hamilton’s strong background in the biotech-verse and roots for Trulance as a long-term winner in the competitive IBS-C playing field.
As SGYP and PGNX both await potential FDA approvals this year, BTIG’s Tim Chiang shares his positive two cents on these drug makers he believes present meaningful upside potential.
H.C. Wainwright spotlights 280% upside potential for Synergy and close to 111% upside potential for Agile ahead of FDA decisions.
Risk-taker Dmitry Balyasny eyes advantage in the biotech world, between new initiations in TEVA, SGYP, and a major increase in OPK.
Canaccord forecasts DTC marketing could be big for SGYP’s Trulance next year, in footsteps of rival Linzess.